Views & Analysis Considerations for Mobile Health Technology Developers: Part... In Part 1 of this series, general wellness devices and mobile me
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
